Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2018-09-12

FDA Approved: LEVETIRACETAM — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

The FDA granted a supplemental labeling/approval for LEVETIRACETAM through Prasco Laboratories under NDA 207958.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LEVETIRACETAM (levetiracetam)

Snippet

SUPPL AP for LEVETIRACETAM (LEVETIRACETAM)